GeneDx Holdings Corp. (WGS)
Nasdaq · Healthcare · Diagnostics & Research
$76.27+4.35%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $2.3B
- Forward P/E
- 63.6
- 52-week range
- $32.21 – $170.87
- 52-week change
- −39.47%
- EPS (trailing)
- −$3.63
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $428M (+39.97%)
- Net income
- −$21.0M
- Operating margin
- −3.1%
- Diluted EPS
- −$0.73
- Free cash flow
- $14.3M
From the company’s annual report on SEC EDGAR.
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Headquarters: Stamford, United States · 1,300 employees · genedx.com